MiNK Therapeutics, Inc. (INKT) Research

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

Market snapshot

Symbol
INKT
Price
$12.14
Day change
-0.57%
Market cap
$60.5M
P/E ratio
-4.67x
52-week range
6.8-76
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$35.00

Peer companies

  • CervoMed Inc. (CRVO)
  • Equillium, Inc. (EQ)
  • Gain Therapeutics, Inc. (GANX)
  • Werewolf Therapeutics, Inc. (HOWL)
  • IO Biotech, Inc. (IOBT)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • OS Therapies Incorporated (OSTX)
  • Outlook Therapeutics, Inc. (OTLK)

Recent insider activity

  • Ryan Barbara — S-Sale (500 shares) on 2026-06-04
  • Ryan Barbara — S-Sale (1000 shares) on 2026-06-04
  • Holcomb John Bradley — A-Award (1091 shares) on 2026-06-01
  • Holcomb John Bradley — A-Award (1239 shares) on 2026-03-02
  • Ryan Barbara — A-Award (1434 shares) on 2026-06-01

Open MiNK Therapeutics, Inc. (INKT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.